Previous 10 | Next 10 |
Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor $937.8 million in cash, cash equivalents and investments at end of Q...
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial...
2023-04-19 10:05:30 ET After losing over a third of the value in the previous session, Relay Therapeutics ( NASDAQ: RLAY ) added ~3% on Wednesday morning as Raymond James upgraded the biotech, noting that the selloff that followed initial clinical data for its cancer drug RL...
2023-04-19 08:38:04 ET Intuitive Machines ( LUNR ) +24% up 24% as JV with KBR bags a $719M NASA contract. VYNE Therapeutics ( VYNE ) +21% a nnounces positive Preclinical data for inhaled formulation of VYN201 in an in Vivo model of idiopathic pulmonary fibrosis...
2023-04-18 13:00:45 ET Relay Therapeutics ( NASDAQ: RLAY ) stock fell ~30% on Tuesday after the company reported initial data for cancer drug RLY-2608. RLY-2608 is currently being evaluated in an ongoing dose-escalation portion of a study called ReDiscover. The mon...
2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...
Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target exposures Confirmed partial response in breast cancer patient with...
2023-04-13 14:20:02 ET Relay Therapeutics ( NASDAQ: RLAY ) gained 14% on Thursday after Raymond James launched its coverage with an Outperform rating and a $29 per share target as the company prepares to release data for its cancer candidate RLY-2608 at an upcoming medical eve...
2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...
2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...